Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial.
暂无分享,去创建一个
Irina Proskorovsky | Alexandra Ward | J Jaime Caro | J. Caro | A. Ward | J. O'brien | T. Kongnakorn | C. Roberts | I. Proskorovsky | Craig S Roberts | Judith A O'Brien | Thitima Kongnakorn
[1] V. Chair,et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the , 2006, Circulation.
[2] J. Hutton,et al. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK , 2006 .
[3] K. Huybrechts,et al. Long term cost-of-illness in stroke: an international review. , 2002, PharmacoEconomics.
[4] A. Garber,et al. Economic foundations of cost-effectiveness analysis. , 1997, Journal of health economics.
[5] K. Furie,et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. , 2008, Stroke.
[6] J Lipscomb,et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. , 1999, Journal of clinical epidemiology.
[7] J. Caro,et al. Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events. , 1999, The American journal of medicine.
[8] B. Gage,et al. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. , 1998, Stroke.
[9] Irene Katzan,et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the , 2006, Stroke.
[10] D. Fryback,et al. Relative Disutilities of 47 Risk Factors and Conditions Assessed with Seven Preference-Based Health Status Measures in a National U.S. Sample: Toward Consistency in Cost-Effectiveness Analyses , 2006, Medical care.
[11] G. Chatellier,et al. Risk of Myocardial Infarction and Vascular Death After Transient Ischemic Attack and Ischemic Stroke: A Systematic Review and Meta-Analysis , 2005, Stroke.
[12] M. Vergouwen,et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study , 2009 .
[13] R. Sacco,et al. The Northern Manhattan Study , 2004 .
[14] P. Touboul,et al. Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis , 2004, Stroke.
[15] L. Lisabeth,et al. Recurrent Stroke Risk Is Higher Than Cardiac Event Risk After Initial Stroke/Transient Ischemic Attack , 2005, Stroke.
[16] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[17] R. Sacco,et al. Risk of Myocardial Infarction or Vascular Death After First Ischemic Stroke: The Northern Manhattan Study , 2007, Stroke.
[18] P. Beck,et al. Health Services Databases in Saskatchewan , 2007 .
[19] R. Sacco,et al. Recurrent stroke and cardiac risks after first ischemic stroke , 2006, Neurology.
[20] R. Collins,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.
[21] Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[22] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[23] M. Hennerici,et al. High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.
[24] C. Mcintosh,et al. Deriving utility scores for co-morbid conditions: a test of the multiplicative model for combining individual condition scores , 2006, Population health metrics.
[25] M. Feinleib. National Center for Health Statistics (NCHS) , 2005 .
[26] S. Ward,et al. A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.
[27] J. Simons,et al. Discontinuation rates for use of statins are high , 2000, British medical journal.
[28] G Scott Gazelle,et al. Stroke: Effect of implementing an evaluation and treatment protocol compliant with NINDS recommendations. , 2003, Radiology.
[29] J. Farmer. High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.
[30] K. Watson. Guidelines for prevention of CVD in women. , 2005, The Journal of family practice.
[31] J. Caro,et al. Estimating survival for cost-effectiveness analyses: a case study in atherothrombosis. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.